CA3007671C - Molecules d'anticorps anti-pd-1 et leurs utilisations - Google Patents

Molecules d'anticorps anti-pd-1 et leurs utilisations

Info

Publication number
CA3007671C
CA3007671C CA3007671A CA3007671A CA3007671C CA 3007671 C CA3007671 C CA 3007671C CA 3007671 A CA3007671 A CA 3007671A CA 3007671 A CA3007671 A CA 3007671A CA 3007671 C CA3007671 C CA 3007671C
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
antibody molecule
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3007671A
Other languages
English (en)
Other versions
CA3007671A1 (fr
Inventor
Sanela Bilic
Jr. Howard Danny Roland
John Scott Cameron
Glenn Dranoff
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority claimed from PCT/US2016/067200 external-priority patent/WO2017106656A1/fr
Publication of CA3007671A1 publication Critical patent/CA3007671A1/fr
Application granted granted Critical
Publication of CA3007671C publication Critical patent/CA3007671C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention concerne des molécules d'anticorps qui se lient spécifiquement à PD-1. Les molécules d'anticorps peuvent être utilisées pour le traitement ou la prévention d'états et de troubles cancéreux ou infectieux.
CA3007671A 2015-12-17 2016-12-16 Molecules d'anticorps anti-pd-1 et leurs utilisations Active CA3007671C (fr)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US201562269044P 2015-12-17 2015-12-17
US62/269,044 2015-12-17
US201662331371P 2016-05-03 2016-05-03
US62/331,371 2016-05-03
US201662344784P 2016-06-02 2016-06-02
US62/344,784 2016-06-02
US201662347331P 2016-06-08 2016-06-08
US62/347,331 2016-06-08
US201662359781P 2016-07-08 2016-07-08
US62/359,781 2016-07-08
US201662381384P 2016-08-30 2016-08-30
US62/381,384 2016-08-30
US201662400787P 2016-09-28 2016-09-28
US62/400,787 2016-09-28
US201662414128P 2016-10-28 2016-10-28
US62/414,128 2016-10-28
US201662431846P 2016-12-09 2016-12-09
US62/431,846 2016-12-09
PCT/US2016/067200 WO2017106656A1 (fr) 2015-12-17 2016-12-16 Molécules d'anticorps anti-pd-1 et leurs utilisations

Publications (2)

Publication Number Publication Date
CA3007671A1 CA3007671A1 (fr) 2017-06-22
CA3007671C true CA3007671C (fr) 2025-11-18

Family

ID=

Similar Documents

Publication Publication Date Title
JP7569166B2 (ja) Ｐｄ－１に対する抗体分子およびその使用
US12600777B2 (en) Combination therapies comprising antibody molecules to LAG-3
US20230013364A1 (en) Combination therapies comprising antibody molecules to pd-1
US10851165B2 (en) Antibody molecules to PD-L1 and methods of treating cancer
US20220133889A1 (en) Combination therapies comprising antibody molecules to tim-3
CA3007671C (fr) Molecules d'anticorps anti-pd-1 et leurs utilisations
RU2788092C2 (ru) Молекулы антител к pd-1 и их применения
HK40102321A (en) Antibody molecules to pd-l1 and uses thereof
EA040861B1 (ru) Молекулы антител к pd-l1 и их применение